The Asthma Control Rate Achieved by Budesonide/Formoterol in Clinical Practice in China

AstraZeneca

Status: Completed

Conditions: Asthma

Treatments: Other: without interventions

Study type: Observational

Funder types: Industry

Identifiers

NCT01785901

NIS-RCN-SYM-2012/1

Details and patient eligibility

About

This is a multi-centre, cross-sectional study planned to be conducted in China. The study aims to observe about 1500 asthma patients who have already received budesonide/formoterol combination treatment by physicians' determination and whose medications are aligned with the package insert of budesonide/formoterol approved in China.

Full description

The asthma control rate achieved by budesonide/formoterol in clinical practice in China.

Enrollment: 1,502 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Clinical diagnosis of asthma at least 6 months;
2. Prescribed with budesonide/formoterol treatment at least 3 months before enrolled;
3. Has used the same maintenance dose of budesonide/formoterol for at least 4 weeks before enrolled.

Exclusion criteria

1. Participation in any clinical study within 3 months;
2. Have COPD history/suspicious COPD;
3. ≥ 10 pack years of smoking history
4. Used any other asthma maintenance medication accompanied with budesonide/formoterol within 3 months before enrolled
5. With asthma exacerbation (defined as asthma symptom deterioration resulting oral/rectal/parenteral GCS medication or emergency room treatment or hospitalisation) within 4 weeks before enrolled

Trial design

1,502 participants in 1 patient group

Target subject population 1500

Description:

Asthma patients who have already received the treatment of budesonide/formoterol by physicians' determination and whose medications are aligned with the package insert of budesonide/formoterol approved in China

Treatment:

Other: without interventions